Objectives
To determine the prevalence of resistance to antimicrobials in Acinetobacter baumannii (A. baumannii) from Spain and to compare it with those obtained in the first national study (GEIH-Ab project 2000).
Methods
A total of 446 isolates of A. baumannii obtained from 43 Spanish hospitals during February-March 2010 were studied. Identification of A. baumannii was confirmed by ARDRA and MALDI-TOF. Susceptibility to 18 antimicrobial agents was determined by microdilution (Clinical and Laboratory Standards Institute, CLSI). The CLSI break-points were used, except for doripenem, rifampin, sulbactam (Societ¨¦ Fran?aise de Microbiologie [SFM] break-points) and tigecycline (European Committee on Antimicrobial Susceptibility Testing [EUCAST] break-points for Enterobacteriaceae).
Results
The percentage of resistant isolates (intermediate susceptible plus resistant) was: > 94 % (ceftazidime, piperacillin and ciprofloxacin), 82-86 % (carbapenems, tetracycline), 60-70 % (tobramycin, sulbactam, gentamicin, doxycycline), 49 % (amikacin), 30 % (minocycline, rifampin), 24 % (tigecycline), and 3 % (colistin). These isolates were, in comparison with those of the first study, more resistant (P < .01) to ceftazidime (99 % vs 83 % ), carbapenems (82-86 % vs 43-48 % ), sulbactam (65 % vs 53 % ) and colistin (3 % vs 0 % ), but more susceptible to aminoglycosides (particularly gentamicin: 70 % vs 96 % of resistant isolates), tetracycline (83 % vs 91 % ) and rifampicin (30 % vs 51 % ).
Conclusion
There is a high prevalence of A. baumannii resistant to antimicrobials, particularly to carbapenems. The resistance to carbapenems, ceftazidime and sulbactam was significantly higher than that observed for isolates from the GEIH-Ab project 2000. The resistance to aminoglycosides, tetracycline and rifampin, however, was significantly decreased.
